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Abstract 78 
Objective: To investigate the role of calcitonin gene-related peptide (CGRP), pituitary adenylate 79 
cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide (VIP) in 80 
cluster headache (CH), we measured these vasoactive peptides interictally and during 81 
experimentally induced CH attacks.   82 
Methods: We included patients with episodic CH in an active phase (n=9), episodic CH patients in 83 
remission (n=9) and in patients with chronic CH (n=13). Cluster headache attacks were induced by 84 
infusion of CGRP (1.5µg/min) in a randomized, double-blind, placebo controlled, two-way cross-85 
over study. At baseline we collected interictal blood samples from all patients and during 11 CGRP-86 
induced CH attacks. 87 
Results: At baseline, episodic CH patients in remission had higher plasma levels of CGRP, 100.6 ± 88 
36.3 pmol/l, compared to chronic CH patients, 65.9 ± 30.5 pmol/l, (p=0.011). Episodic CH patients 89 
in active phase had higher PACAP38 levels, 4.0 ± 0.8 pmol/l, compared to chronic CH patients, 3.3 90 
± 0.7 pmol/l, (p=0.033). Baseline levels of VIP did not differ between CH groups. We found no 91 
attack-related increase in CGRP, PACAP38 or VIP levels during CGRP-induced CH attacks. 92 
Conclusions: This study suggests that CH disease activity is associated with alterations of CGRP 93 
expression. Future studies should investigate the potential of using CGRP measurements in 94 
monitoring of disease state and predicting response to preventive treatments including response to 95 
anti-CGRP monoclonal antibodies. 96 
 97 
 98 
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 100 
Introduction 101 
The hallmark of cluster headache (CH) is periodicity and prominent cranial autonomic symptoms 102 
(CAS) 1. Most patients report periodicity by experiencing episodic CH with month long attack 103 
periods separated by remission periods 2. To what extent mechanisms underlying CAS contribute to 104 
initiation of CH attacks is still not fully elucidated. The trigemino-autonomic reflex activation is 105 
associated with release of sensory and parasympathetic neuropeptides 3 such as calcitonin gene-106 
related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) and 107 
vasoactive intestinal polypeptide (VIP).  Studies investigating plasma levels of these neuropeptides 108 
in CH remain, however, scarce and conflicting 4–8. Elevated plasma CGRP, VIP and PACAP38 109 
have been reported during spontaneous and glyceryl trinitrate (GTN) provoked CH attacks 5–7,9. The 110 
diverging methodologies of these studies, however, make it difficult to compare findings across 111 
studies. To date, no studies have investigated the role of these vasoactive peptides in chronic CH 112 
patients. In addition, it is unknown whether plasma levels correlate to disease periodicity. As CH is 113 
unpredictable and short lasting, investigation of patients during spontaneous attacks can be 114 
immensely difficult. This challenge can be overcome by studying provoked CH attacks in a 115 
controlled setting 5. Recently, we demonstrated that CGRP infusion could provoke CH attacks in 116 
patients in an active disease state (episodic CH in active phase and chronic CH patients), but not in 117 
patients during remission 10.  118 
We hypothesized that baseline levels of CGRP, VIP and PACAP38 would be elevated in 119 
episodic and chronic CH patients in an active disease state compared to patients in remission. 120 
Furthermore, we hypothesized that CGRP-induced CH attacks would cause a further increase in 121 
plasma levels of neuropeptides. To test these hypotheses, we investigated plasma CGRP, VIP and 122 
PACAP38 at baseline and during CGRP induced CH attacks. In addition, we compared the baseline 123 
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concentration of neuropeptides in CH patients with historical data on migraine patients and healthy 124 
controls.  125 
 126 
Materials and Methods 127 
Patients were eligible for inclusion if they were aged 18 – 65 years and had a verified diagnosis of 128 
episodic or chronic cluster headache as defined by the International Headache Society classification 129 
(Headache Classification Committee of the International Headache Society (ICHD-3 beta), 2013) 130 
11. We recruited participants from the outpatient clinic at the Danish Headache Center 131 
(Rigshospitalet-Glostrup) in the period from December 2015 to April 2017. The present study is a 132 
predefined part of a larger parent protocol (protocol H-15006836, clinicaltrials.gov identifier 133 
NCT02466334). The first part of the study investigated the ability of CGRP to induce cluster 134 
headache like attacks and has previously been described in detail 10. Patients were eligible for 135 
inclusion in the study if they were in active disease phase, defined as occurrence of typical CH 136 
attacks within the last 30 days; or in remission, defined as attack-free for at least 30 days. Episodic 137 
patients could participate in remission and in active disease phase. According to the ICHD-3 beta 138 
criteria, chronic patients did not have attack-free periods exceeding 30 days in the last 12 months. 139 
Exclusion criteria included any other type of headache (apart from episodic tension-type headache ≤ 140 
5 days per month), any previous serious somatic or psychiatric condition, pregnant or nursing 141 
women, drug misuse or daily intake of medication other than preventive treatment for CH. All 142 
patients underwent a full medical examination and in women of childbearing age pregnancy testing 143 
was conducted prior to participation. 144 
The study was approved by the Regional Committee on Health Research Ethics of the Capital 145 
Region (H-15006836) and was conducted in accordance with Helsinki II Declaration of 1964, with 146 
later revisions. The study was registered at clinicaltrials.gov (identifier NCT02466334) and 147 
  A. Snoer et al. 
 7 
approved by the Danish Data Protection Agency. All patients received oral and written information 148 
about the study and were given time for consideration before giving their written consent to 149 
participate.  150 
In the present study we conducted post hoc analyses which included previously published data on 151 
migraine patients and healthy volunteers 12 (ClinicalTrials.gov identifier NCT01841827). All 152 
samples from previous data were collected in an inter-ictal state, defined as the participant being 153 
completely headache- and analgesic free for a minimum of 48-hours prior to sampling. Samples 154 
were analyzed by the same assays in the same laboratory as the current study 12.  155 
Design and experimental protocol 156 
The study was conducted as a randomized, double-blind, placebo controlled, two-way cross-over 157 
study. All patients were randomly allocated to receive a continuous infusion (Braun Perfusor, 158 
Melsungen, Germany) with either 30 µg CGRP (1.5µg/min) (Calbiochem® and PolyPeptide group) 159 
or placebo (saline) over 20 min on two separate days. CGRP and placebo were prepared in identical 160 
vials and randomized by the regional central pharmacy. Allocation was balanced to ensure 161 
approximately even numbers of participants receiving CGRP first and placebo last or vice versa. 162 
The randomization code remained in the hospital during the study and was unavailable to 163 
investigators until study completion. 164 
On both experimental days, patients with episodic (active phase) and chronic cluster headache 165 
reported themselves to the clinic when they were headache/attack free for at least 3 and 8 hours, 166 
respectively. An 8-hour headache-free-interval prior to provocation was initially set for both episodic 167 patients in cluster and chronic cluster patients, but due to feasibility concerns, a revised 3-hour 168 headache-free-interval was set in order to include episodic patients with a high mid-cluster attack 169 burden.   170 
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All participants were asked to retrospectively estimate their attack frequency in the preceding 30 171 
days. Patients were placed in a supine position and a venous catheter (Venflon®) inserted in the 172 
cubital vein on the right or left arm for CGRP infusion and drawing of blood samples. Patients were 173 
at rest for 15 min before obtaining baseline status. Blood for analysis of CGRP, PACAP38 and VIP 174 
was drawn at fixed time points: At baseline (T0), post infusion (T20), 10 min (T30) and 70 min post 175 
infusion (T90). If the patient developed a CH-like attack during the observations period, blood was 176 
drawn at the onset phase of attack (Ta0), after 15 min (Ta15) and at 30 min after the start of the 177 
attack (Ta30).  178 
Blood collection and processing 179 
Blood was drawn through the venous catheter and connector using two 20 ml syringes. For blood 180 
sampling the first 5 ml were discarded and after the procedure the catheter was flushed with saline. 181 
The blood was thereafter transferred into different tubes: precooled lithium heparin tubes containing 182 
aprotinin (Trasylol®) for VIP; precooled EDTA tubes with aprotinin for PACAP38 and standard 183 
EDTA tubes for CGRP. All tubes were inverted several times. The precooled tubes were stored in a 184 
cooling box (5˚C) and the rest stored at room temperature for 20 min until centrifugation. The tubes 185 
were centrifuged together at 4˚C at 1851g for 10 min. Plasma was thereafter transferred to 186 
polypropylene tubes (Greiner Cryo.s ™) and stored at -25˚C until analysis.  187 
Radioimmunoassay 188 
Plasma CGRP concentrations were measured with a fully evaluated radioimmunoassay for human 189 
CGRP, as described previously (Schifter, 1991) 12,13. The tracer was prepared by the method of 190 
Iodogeneral (Pierce, Rockford, IL, USA)14 by iodination of [Tyr0] α-CGRP (25-37) amide and 191 
purification by high liquid chromatography (HPLC). Samples, antibody and calibrators were 192 
incubated at 4°C for about 90 hours before addition of tracer and subsequent incubation for 48 193 
hours. Free and antibody-bound tracer was separated by Sac-Cel separation.  194 
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Plasma concentration of PACAP38 195 
The concentration of PACAP38 in plasma was measured radioimmunochemically using antiserum 196 
733C-5 directed against the sequence PACAP28–38 15. The antiserum which was used at a final 197 
titer of 1.2 × 105 in a total volume of 0.8 ml/tube does not cross-react with PACAP27, VIP or other 198 
structurally related peptides. Synthetic PACAP28–38 labeled to a specific radioactivity of 30 199 
Bq/mol with 125I by the iodogen method was used as tracer and synthetic human PACAP38 was 200 
used as standard. The IC50 value (the concentration of PACAP38 giving 50% displacement of the 201 
tracer) was 17 pmol/l and the intra-assay and inter-assay coefficient of variation values were 3.1 and 202 
10.1%, respectively. 203 
Since PACAP38 in human plasma is bound to the protein ceruloplasmin 16 the peptide was freed 204 
from ceruloplasmin before measurement by the following procedure: 1.2 ml of 1% trifluoroacetic 205 
acid was added to an equal volume of plasma from each subject and mixed thoroughly for 60 s. 206 
After incubation for 10 min in an ice-bath, the mixture was neutralized by addition of 15 μl of 5 M 207 
NaOH. Subsequently 2.5 ml of absolute ethanol was added. After thorough mixing, followed by 208 
centrifugation at 1500 g for 20 min at 4 °C, the supernatant was decanted and dried under vacuum. 209 
The dried product was reconstituted to its original volume with assay buffer for assay.  210 
Plasma concentration of VIP 211 
The concentration of VIP in plasma, after extraction with absolute ethanol, was measured by the 212 
VIP radioimmunoassay using antiserum 5603–6 at a final titer of 1.2 × 106 in a total volume of 0.8 213 
ml/tube 17,18. This antiserum recognizes the mid- and C-terminal regions of the VIP molecule 214 
(sequence 11–24) and displays no cross-reactivity with other known gastrointestinal peptides or 215 
neuropeptides. The label has a specific radioactivity of 0.92 nCi/fmol (~34 Bq/fmol). The IC50 216 
value (the concentration of VIP giving 50% displacement of label) was 24 pmol/l and the intra-217 
assay and the inter-assay coefficient of variation values were 8.7 and 12.6%, respectively.   218 
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Headache characteristics and vital signs 219 
From baseline (T-10 and T0) and throughout the entire experiment the following variables were 220 
recorded every 10 min: Headache intensity on a verbal rating scale (VRS) from 0 to 10 (0; no 221 
headache, 1; very mild headache, 10; worst imaginable headache); quality of pain (stabbing, 222 
throbbing, pulsating or resembling usual CH attack); headache localization and accompanying 223 
symptoms, these including CAS. In addition, we recorded blood pressure and heart rate. Symptoms 224 
experienced outside recording intervals were documented separately. 225 
Statistical analysis 226 
All absolute values are presented as mean ± standard deviation. The primary endpoints were: 1) 227 
Differences of biochemical variables (CGRP, PACAP38 and VIP) in between groups (episodic CH 228 
patients in active phase, episodic CH patients in remission and chronic CH patients) at baseline; 2) 229 
Differences over time in plasma concentrations of biochemical variables between patients 230 
developing an attack and those who did not. 3) Differences in plasma concentrations over time of 231 
biochemical variables between active and placebo days.  232 
Distribution of demographical data was tested using the D’Agostino and Pearson normality test and 233 
group comparisons of demographical data were subsequently analyzed using parametric statistics. 234 
Evaluation of baseline variables was done using a generalized linear model with repeated 235 
measurements.  236 
To analyze for an effect of CGRP infusion on biochemical variables we used repeated 237 
measurements analysis with random effect of subjects, attacks and further of subjects’ times day. In 238 
this way we allow for correlation between measurements on the same individual, and additional 239 
correlation between measurements in the same individual on the same day. The measurement taken 240 
at time zero was used as baseline variable in the repeated measurements model. For each of the 241 
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responses VIP, PACAP and CGRP we checked model assumptions and transformed the response 242 
variables as appropriate to meet model requirements. Correlations between baseline levels and time 243 
since last attack, were calculated using Pearson correlation test.   244 
We used GraphPad Prism 7.02, SAS Enterprise and R 3.4.3 for statistical analyses. All p-values 245 
were two-sided and considered significant if <0.05. 246 
Data availability 247 
The data supporting the findings of this study are not publicly available, but will be shared, in an 248 
anonymized form, by request from any qualified investigator. 249 
Results 250 
In total 31 patients (26 men and 5 women) completed the study (Fig. 1). The mean age was 37 251 
years, (range 19 – 59). Nine patients reported episodic CH in active phase (6 men, 3 women; mean 252 
age 32, range 19 – 56 years), 9 episodic in remission (all men; mean age 32, range 22 – 43 years), 253 
and 13 chronic CH (10 men, 3 women; mean age 42, range 26 – 59 years). Clinical data on patients 254 
are shown in table 1. Episodic patients in remission reported remission on average for 6.6 (range 255 
1.3–18.0) months prior to participation in the study. At baseline, blood samples were collected in all 256 
31 patients for VIP and CGRP, but samples from one patient were lost for PACAP38. CGRP 257 
infusion induced a CH-like attack in 16 out of 31 patients, of these non in episodic patients in 258 
remission. We collected blood samples during 11 out of 16 CH attacks and all attack samples were 259 
collected prior to abortive treatment. In the remaining 5 attacks, symptoms subsided before we had 260 
the chance to engage attack sampling protocol. All provoked attacks were unilateral, located in the 261 
periorbital region and were accompanied by CAS and/or restlessness. The median severity of 262 
provoked attacks was 10 (IQR 4 – 10, range 1 – 10) and median number of accompanying 263 
symptoms was 4 (IQR 1.5 – 5, range 1 – 8).  Characteristics of 11 provoked attacks are listed in 264 
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table 2. The concentration of CGRP, PACAP38 and VIP were above the detection limit in all blood 265 
samples. 266 
CGRP  267 
We found significantly higher baseline plasma CGRP in episodic patients in remission, 100.6 ± 268 
36.3 pmol/l, compared to chronic patients, 65.9 ± 30.5 pmol/l, (p=0.011) (Fig. 2, table 3). The 269 
repeated measurements analysis showed no independent increase of plasma CGRP in patients who 270 
reported a CH-like attack after provocation with CGRP (p=0.36). After CGRP infusion plasma 271 
levels of CGRP increased significantly, 574.3 ± 296.4 pmol/l, compared to baseline, 81.7 ± 33.4 272 
pmol/l, (p<0.0001). We found no changes in CGRP levels after placebo infusion compared to 273 
baseline (p=0.43). 274 
PACAP38  275 
We found significantly higher baseline PACAP38 levels in episodic patients in active phase, 4.0 ± 276 
0.8 pmol/l, compared to chronic patients, 3.3 ± 0.7 pmol/l, (p=0.033) (table 3). CGRP induced CH 277 
attacks were not associated with changes in plasma PACAP38 (p=0.29). Compared to baseline, 278 
plasma levels of PACAP38 remained unchanged after CGRP (p=0.66) and placebo (p=0.57) 279 
infusion.  280 
VIP  281 
We found no differences in baseline plasma levels of VIP between CH groups (p > 0.05) (table 3). 282 
The repeated measurements analyses revealed a significant decrease in patients who reported a 283 
provoked attack (p=0.013).  Infusion of CGRP caused a significant increase in plasma VIP 284 
compared to baseline (p<0.001), but not after placebo (p=0.53). 285 
Post hoc analysis 286 
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We compared five groups: Episodic patients in active phase; episodic patients in remission; chronic 287 
patients; migraine without aura patients and healthy controls (Fig. 2). The analysis revealed that 288 
episodic patients in bout (p<0.001), patients in remission (p<0.001) and chronic patients (p=0.020) 289 
had higher baseline levels of CGRP compared to healthy controls. Furthermore, patients in active 290 
phase (p<0.001) and in remission (p<0.001) had higher CGRP levels compared to migraine 291 
patients. We found no differences in PACAP38 and VIP levels between CH patients, migraine 292 
patients and healthy controls.  293 
In patients in an active disease state we found no difference in baseline CGRP, PACAP38 nor VIP 294 
levels in patients on prophylactic treatment vs. those without (p>0.05). There was no correlation 295 
between hours since last attack, nor 30-day attack burden and baseline level of CGRP, PACAP38 296 
nor VIP (p>0.05).  297 
 298 
Discussion 299 
The main finding of the present study was that CH patients in remission had higher baseline levels 300 
of CGRP, but not VIP or PACAP38, compared to chronic CH patients. Furthermore, CGRP-301 
induced CH attacks were not associated with elevated levels of CGRP, VIP or PACAP38. In 302 
addition, CH-patients irrespective of disease state had higher plasma levels of CGRP compared to 303 
migraine patients and healthy controls.  304 
A novel finding of the present study was that chronic CH patients had lower plasma CGRP 305 
compared to CH patients in remission. This suggests that plasma levels of CGRP may fluctuate 306 
with disease activity. The results are very interesting when viewed in the light of recent press 307 
releases on the preventive effect of the anti-CGRP monoclonal antibodies in episodic patients in 308 
active period, but not in patients with chronic CH. Interestingly, poor treatment response in chronic 309 
CH is reported across different treatment modalities indicating basic pathophysiological differences 310 
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in between phenotypes 19,20. The question is why chronic CH patients had lower CGRP levels than 311 
CH patients in remission and episodic CH patients in active phase? Furthermore, how the regulation 312 
of CGRP expression and release aligns with our data is difficult to reconcile but CGRP expression 313 
is regulated in many ways. Animal experiments reported local elevated CGRP levels after nerve 314 
damage, nerve regeneration and inflammatory response 21. CGRP is expressed and released from C 315 
fibers and its receptors are present in A delta fibers 22. In man, application of capsaicin to the nasal 316 
mucosa led to immediate release of CGRP in saliva and plasma 8. It is possible that secreted CGRP 317 
may act in an autocrine fashion to further increase CGRP release in a positive feedback loop, a 318 
mechanism possibly implicated in peripheral sensitization 23. In rats, a single subcutaneous 319 
capsaicin injection in the hind-paw depleted CGRP levels in the skin and sciatic nerve after 8 and 320 
10 days 24,25. Interestingly, repeated capsaicin applications to the nasal mucosa resulted in 321 
desensitization and time-dependent recovery of responses 26. In addition, intradermal capsaicin 322 
injections produced a steady increase of CGRP levels in the first sampling period but failed to reach 323 
significance in the second session 27. Thus, capsaicin-induced desensitization of sensory afferents 324 
might lead to depletion of neuropeptide release from afferents or decreased activity of transient 325 
receptor potential vanilloid 1 channels 28,29. Taken together these data suggest that chronic CH 326 
patients may exhibit low plasma CGRP due to depletion of CGRP from trigeminal afferents. 327 
Whether a CH attack represents a comparable stimulus to capsaicin is unknown, but it is possible 328 
that endogenous processes influence CGRP expression. Several factors might have influenced our 329 
data. We tested for possible influence of a recent attack and attack burden (frequency) and found 330 
that CGRP levels were not associated to the most recent attack or to attack burden in the 30 days 331 
preceding baseline sampling. Exogenous factors such use of preventive and abortive treatments may 332 
theoretically influence CGRP expression. One study reported that treatment with corticosteroids can 333 
reduce CGRP levels in episodic CH patients 4. In the present study 61.5% of chronic CH patients 334 
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took preventive treatments compared to 44.4 % of episodic CH patients, but an exploratory analysis 335 
revealed no difference in baseline levels. Preclinical studies reported that application of 5-HT1 336 
receptor agonist decreased the synthesis of CGRP in trigeminal ganglion 30 and that 7 day infusion 337 
of sumatriptan infusion upregulated CGRP expression in trigeminal dural afferents 31. In the present 338 
study, we did not record the patients use of triptans prior to baseline sampling, but in future studies 339 
investigating CGRP in CH, this should be taken into consideration.  340 
In the post hoc analyses we found that episodic patients in active phase and in remission had 341 
higher baseline levels of CGRP than episodic migraine patients and healthy controls. Although data 342 
from migraine patients and healthy controls derived is historical and thus should be interpreted with 343 
caution, it is an interesting observation. One study reported that chronic migraine patients had 344 
higher CGRP levels than episodic migraine patients, healthy controls or episodic CH patients in 345 
remission 32. This study also reported no difference between patients with episodic migraine and 346 
CH patients 32. As different assays have been used across studies in migraine and CH it is 347 
impossible to compare results directly and further hypothesis-based studies are necessary to address 348 
possible difference in CGRP levels between cluster headache and migraine.  349 
Collectively, our data suggest that CGRP may be altered in CH, but the findings should be 350 
reproduced in a larger cohort of CH patients, ideally in prospective studies investigating changes in 351 
CGRP over time and disease state.  352 
In the present study chronic CH patients had lower baseline levels of PACAP38 compared to 353 
episodic patients in bout, but similar levels compared to CH patients in remission. In line with our 354 
CGRP findings in chronic CH patients, this suggests possible pathophysiological differences 355 
between disease states. Another important finding was that CGRP-induced CH attacks were not 356 
associated with alterations in plasma PACAP38 or VIP. These data are in contrast to previous 357 
studies, where VIP 7 and PACAP38 9 were reported elevated during spontaneous attacks. In the 358 
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current study chronic patients had an average longer disease duration compared to episodic patients, 359 
which might be an influencing factor. A migraine study reported that baseline levels of PACAP38 360 
were negatively correlated with disease duration 33, suggesting that longer disease duration or 361 
transition to the chronic phase alters the regulation of this peptide. In support, repeated chemical 362 
stimulation of dura surrounding the superior sagittal sinus decreased PACAP38 levels in the TG in 363 
rats 34. Both PACAP38 and VIP may be considered as markers of parasympathetic activation. 364 
Higher PACAP38 levels in episodic CH patients in active phase compared to chronic patients could 365 
theoretically reflect marked parasympathetic activation, but as VIP was unchanged, this 366 
interpretation remains speculative. To notice, we found no correlation between hours since last 367 
attack and baseline VIP or PACAP38 levels, as would be expected given the short half-lives (min) 368 
of VIP and PACAP38 35. Infusion of CGRP induced an increase in VIP, but not PACAP38, and 369 
development of an attack was associated with a decrease in VIP. As VIP levels were highest 370 
immediately following infusion and attacks occurred on average 34 min after onset of infusion, the 371 
observed attack-associated decrease in VIP was likely to coincide with the natural fall in VIP. 372 
Interestingly, our previous study using the same assay also found elevated VIP after CGRP infusion 373 
in migraine patients 12. These findings suggest that CGRP infusion is associated with transient 374 
elevation of plasma VIP, but it does not seem to be associated with attack development. 375 
Collectively, CH disease activity was not associated with elevation of PACAP38 and VIP. 376 
Furthermore, CGRP induced CH attack did not increase plasma VIP and PACAP38, which is in 377 
contrast to previous studies 7,9. The inconsistency of results across studies is likely attributed to use 378 
of different assays 35. 379 
We collected blood from the antecubital vein, and not from the external jugular vein. 380 
One might argue that plasma levels should be collected in the cranial outflow. In migraine patients, 381 
elevated plasma CGRP was reported elevated in peripheral blood ictally 36 and interictally 37. One 382 
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study in migraine patients reported no changes in plasma CGRP during attacks. To date, no studies 383 
have compared plasma PACAP38 and VIP between the two sampling sites, but elevated levels of 384 
these neuropeptides were reported in peripheral blood during and outside of migraine attacks 9,33. 385 
We acknowledge relatively small sample size in the present study. However, we obtained two sets 386 
of samples for baseline-comparisons (in total 62 samples) and performed a robust statistical 387 
analysis. We collected “attack samples” in 11 patients. Previous studies reported plasma alterations 388 
during and spontaneous attacks on average of 14 patients 5–7,9. Thus, the present sample size should 389 
be sufficient to detect possible attack related changes in neuropeptides. As blood samples were not 390 
drawn in all provoked attack and element of selection bias might affect attack results. However, as 391 
these results were negative, the concern for this bias seems less important. With regards to 392 
sensitivity and specificity of CGRP assay used in the current study, we measured a robust elevation 393 
of CGRP after CGRP infusion and importantly no concomitant increase in PACAP38, which is 394 
structurally similar.   395 
The present study demonstrated that CH disease activity might be associated with 396 
alterations of CGRP expression, possibly PACAP38 but not VIP expression. Future studies should 397 
investigate the potential of using CGRP measurements in monitoring of disease state and predicting 398 
response to preventive treatments including response to anti-CGRP monoclonal antibodies.  399 
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Article highlights: 406 
• The present study demonstrated that cluster headache disease activity is associated with 407 
alterations of CGRP expression, possibly PACAP38 but not VIP expression 408 
• Our results indicate that there are basic pathophysiological differences between episodic and 409 
chronic cluster headache patients 410 
• The observed lower CGRP levels in chronic cluster headache patients at baseline might 411 
offer an explanation to why anti-CGRP monoclonal antibodies have proven effective in 412 
episodic, but not in chronic cluster headache patients 413 
 414 
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 420 
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 428 
 429 
 430 
  A. Snoer et al. 
 19 
References 431 
1.  Third Headache Classification Committee. The International Classification of Headache 432 
Disorders, 3rd edition. Cephalagia 2018;38(1):1–211. 433 
2.  Fischera M, Marziniak M, Gralow I, Evers S. The incidence and prevalence of cluster 434 
headache: A meta-analysis of population-based studies. Cephalalgia 2008;28(6):614–618. 435 
3.  McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: 436 
functional role in cerebrovascular regulation. Proc. Natl. Acad. Sci. U. S. A. 437 
1986;83(15):5731–5. 438 
4.  Neeb L, Anders L, Euskirchen P, et al. Corticosteroids alter CGRP and melatonin release in 439 
cluster headache episodes. 2015;35(4):317–326. 440 
5.  Fanciullacci M, Alessandri M, Sicuteri R, Marabini S. Responsiveness of the 441 
trigeminovascular system to nitroglycerine in cluster headache patients. Brain 442 
1997;120(2):283–288. 443 
6.  Fanciullacci M, Alessandri M, Figini M, et al. Increase in plasma calcitonin gene-related 444 
peptide from the extracerebral circulation during nitroglycerin-induced cluster headache 445 
attack. Pain 1995;60(2):119–123. 446 
7.  Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in 447 
cluster headache nEuropeptide changes and effects of acute attacks therapies. Brain 1994;117 448 
( Pt 3(3):427–434. 449 
8.  Nicolodi M. Nostril capsaicin application as a model of trigeminal primary sensory neuronal 450 
activation. Cephalalgia 1994;14(2):134–138. 451 
9.  Tuka B, Szabó N, Tóth E, et al. Release of PACAP-38 in episodic cluster headache patients – 452 
  A. Snoer et al. 
 20 
an exploratory study. J. Headache Pain 2016;17(1):69. 453 
10.  Vollesen ALH, Snoer A, Beske RP, et al. Effect of Infusion of Calcitonin Gene-Related 454 
Peptide on Cluster Headache Attacks. JAMA Neurol. 2018; 455 
11.  Headache Classification Committee International Headache Society. ICHD-3 Beta - The 456 
international classification of headache disorders 3rd edition (beta version). 2016. 457 
12.  Guo S, Vollesen ALH, Hansen YBL, et al. Part II: Biochemical changes after pituitary 458 
adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia 459 
2017;37(2):136–147. 460 
13.  Schifter S. Circulating concentrations of calcitonin gene-related peptide (CGRP) in normal 461 
man determined with a new, highly sensitive radioimmunoassay. Peptides 1991;12(2):365–462 
369. 463 
14.  Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble 464 
chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem. Biophys. Res. 465 
Commun. 1978;80(4):849–857. 466 
15.  Hannibal J, Mikkelsen JD, Clausen H, et al. Gene expression of pituitary adenylate cyclase 467 
activating polypeptide (PACAP) in the rat hypothalamus. Regul Pept 1995;55(2):133–148. 468 
16.  Tams JW, Johnsen AH, Fahrenkrug J. Identification of pituitary adenylate cyclase-activating 469 
polypeptide1-38-binding  factor in human plasma, as ceruloplasmin. Biochem. J. 1999;341 ( 470 
Pt 2:271–276. 471 
17.  Fahrenkrug, J. de Muckadell OBS. Distribution of vasoactive intestinal polypeptide (VIP) in 472 
the porcine central nervous system. J. Neurochem. 1978;31(6):1445–1451. 473 
  A. Snoer et al. 
 21 
18.  Fahrenkrug J, Schaffalitzky de Muckadell OB. Radioimmunoassay of vasoactive intestinal 474 
polypeptide (VIP) in plasma. J. Lab. Clin. Med. 1977;89(6):1379–1388. 475 
19.  Göbel H, Lindner V, Heinze A, et al. Acute therapy for cluster headache with sumatriptan: 476 
Findings of a one- year long-term study. Neurology 1998;51(3):908–911. 477 
20.  Kudrow L. Response of Cluster Headache Attacks to Oxygen Inhalation. Headache J. Head 478 
Face Pain 1981;21(1):1–4. 479 
21.  Donnerer J, Stein C. Evidence for an Increase in the Release of CGRP from Sensory Nerves 480 
during Inflammation. Ann. N. Y. Acad. Sci. 1992;657(1):505–506. 481 
22.  Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing 482 
CGRP and CGRP receptors in the peripheral trigeminovascular system. J. Pain 483 
2013;14(11):1289–303. 484 
23.  Walsh DA, Mapp PI, Kelly S. Calcitonin gene-related peptide in the joint: Contributions to 485 
pain and inflammation. Br. J. Clin. Pharmacol. 2015;80(5):965–78. 486 
24.  Donnerer J, Amann R, Schuligoi R, Skofitsch G. Complete recovery by nerve growth factor 487 
of neuropeptide content and function in capsaicin-impaired sensory neurons. Brain Res. 488 
1996;741(1–2):103–108. 489 
25.  Schicho R, Skofitsch G, Donnerer J. Regenerative effect of human recombinant NGF on 490 
capsaicin-lesioned sensory neurons in the adult rat. Brain Res. 1999;815(1):60–69. 491 
26.  Geppetti P, Fusco BM, Marabini S, et al. Secretion, pain and sneezing induced by the 492 
application of capsaicin to the nasal mucosa in man. Br. J. Pharmacol. 1988;93(3):509–14. 493 
27.  Geber C, Fondel R, Krämer HH, et al. Psychophysics, Flare, and Neurosecretory Function in 494 
  A. Snoer et al. 
 22 
Human Pain Models: Capsaicin Versus Electrically Evoked Pain. J. Pain 2007;8(6):503–14. 495 
28.  Amann R. Desensitization of capsaicin-evoked neuropeptide release - Influence of Ca2+and 496 
temperature. Naunyn. Schmiedebergs. Arch. Pharmacol. 1990; 497 
29.  Zhou Y, Long H, Ye N, et al. The effect of capsaicin on expression patterns of CGRP in 498 
trigeminal ganglion and trigeminal nucleus caudalis following experimental tooth movement 499 
in rats. J. Appl. Oral Sci. 2016;24(6):597–606. 500 
30.  Durham PL, Sharma R V, Russo  a F. Repression of the calcitonin gene-related peptide 501 
promoter by 5-HT1 receptor activation. J. Neurosci. 1997;17(24):9545–53. 502 
31.  De Felice M, Ossipov MH, Wang R, et al. Triptan-induced latent sensitization a possible 503 
basis for medication overuse headache. Ann. Neurol. 2010;67(3):325–37. 504 
32.  Cernuda-Morollón E, Larrosa D, Ramón C, et al. Interictal increase of CGRP levels in 505 
peripheral blood as a biomarker for chronic migraine. Neurology 2013;81(14):1191–1196. 506 
33.  Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in 507 
the plasma during ictal and interictal periods of migraine patients. Cephalalgia 508 
2013;33(13):1085–1095. 509 
34.  Han X, Ran Y, Su M, et al. Chronic changes in pituitary adenylate cyclase-activating 510 
polypeptide and related receptors in response to repeated chemical dural stimulation in rats. 511 
Mol. Pain 2017;13:1–10. 512 
35.  Frederiksen SD, Haanes KA, Warfvinge K, Edvinsson L. Perivascular neurotransmitters: 513 
Regulation of cerebral blood flow and role in primary headaches. J. Cereb. Blood Flow 514 
Metab. 2017;0271678X1774718. 515 
  A. Snoer et al. 
 23 
36.  Gallai V, Sarchielli P, Floridi A, et al. Vasoactive Peptide Levels in The Plasma of Young 516 
Migraine Patients With and Without Aura Assessed Both Interictally and Ictally. Cephalalgia 517 
1995;15(5):384–390. 518 
37.  Ashina M, Bendtsen L, Jensen R, et al. Evidence for increased plasma levels of calcitonin 519 
gene-related peptide in migraine outside of attacks. Pain 2000;86(1–2):133–138. 520 
  521 
  A. Snoer et al. 
 24 
Figure 1. Flow chart of recruitment and inclusion of patients.  522 
 523 
  524 
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Figure 2. Baseline levels of CGRP, VIP and PACAP38 presented as means and SD.  525 
Dashed lines divide present data from historical data. Significant findings according to primary 526 
endpoints marked. Significant finings in post hoc analyses comparing CH patients to data from 527 
historical data: CGRP, eCHr and eCHa > HC, p<0.001; eCHr > MO, p<0.001; eCHa>MO, 528 
p<0.001; cCH > HC, p=0.020. No differences regarding VIP and PACAP38 levels between CH 529 
patients and MO or HC patients were found.   530 
cCH = chronic cluster headache; eCHa = episodic cluster headache patient in active phase; eCHr = 531 
episodic cluster headache in remission; MO = Migraine without aura; HC = Healthy controls; 532 
CGRP = Calcitonin gene-related peptide; PACAP38 = pituitary adenylate cyclase-activating 533 
polypeptide-38; VIP = Vasoactive intestinal peptide.  534 
 535 
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Table 1. Clinical data on patients with episodic cluster headache in active phase (eCHa), remission 537 
(eCHr) and chronic cluster headache (cCH).     538 
 539 
eCHa = episodic cluster headache patient in active phase; eCHr = episodic cluster headache patients 540 
in remission; cCH = chronic cluster headache patients; SD = standard deviation, W/M = 541 
Women/Men. *Treatments: Verapamil 400mg; Verapamil 560mg; Verapamil 400 mg; Recent 542 
blockade greater occipital nerve. ** Treatments: Verapamil 400mg; Verapamil 800mg. *** 543 
Treatments: Verapamil 440mg; Verapamil 480mg; Verapamil 100mg; Verapamil 400mg and 544 
Melatonin 8mg, Verapamil 240mg, Verapamil 600mg; Verapamil 240mg and Lithium 200mg; 545 
Sphenopalatine ganglion neurostimulation and melatonin 4mg.  546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
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Table 2.  Clinical characteristics of provoked attacks in 11 patients. 557 
 558 
Headache intensity: 0 – 10 Verbal response scale. Ta0: Attack onset, prior to acute therapy. Ta15 559 
and Ta30: 15 and 30 min after attack onset respectively. Acute therapy: Suma = sumatriptan 6mg 560 
sc; Oxy = oxygen 15L/min Optimask; SPG = The Pulsante SPG Microstimulator System; Dic = 561 
Diclofenac 25mg sc. Accompanying symptoms: lac = lacrimation; pto = ptosis; mio = miosis; con = 562 
nasal congestion; inj = conjunctival injection; swe = forehead and facial sweating; res = 563 
restlessness; rhi = rhinorrhea; ede = eyelid edema. 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
 573 
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Table 3. Levels of CGRP, PACAP38 and VIP at baseline, presented in means ± SD.  575 
 576 
eCH = episodic cluster headache; cCH = chronic cluster headache; CGRP = calcitonin gene-related 577 
peptide; PACAP38 = pituitary adenylate cyclase-activating polypeptide-38; VIP = vasoactive 578 
intestinal polypeptide 579 
 580 
